Cisplatin-based adjuvant chemotherapy in patients with completely resected non–small-cell lung cancer International Adjuvant Lung Cancer Trial Collaborative Group New England Journal of Medicine 350 (4), 351-360, 2004 | 3016 | 2004 |
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by … M Pfreundschuh, L Trümper, A Österborg, R Pettengell, M Trneny, K Imrie, ... The lancet oncology 7 (5), 379-391, 2006 | 2539 | 2006 |
DNA repair by ERCC1 in non–small-cell lung cancer and cisplatin-based adjuvant chemotherapy KA Olaussen, A Dunant, P Fouret, E Brambilla, F André, V Haddad, ... New England Journal of Medicine 355 (10), 983-991, 2006 | 2353 | 2006 |
A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy RA Olie, AP Simões-Wüst, B Baumann, SH Leech, D Fabbro, RA Stahel, ... Cancer research 60 (11), 2805-2809, 2000 | 950 | 2000 |
CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the … M Pfreundschuh, E Kuhnt, L Trümper, A Österborg, M Trneny, L Shepherd, ... The lancet oncology 12 (11), 1013-1022, 2011 | 854 | 2011 |
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma A Scherpereel, P Astoul, P Baas, T Berghmans, H Clayson, P De Vuyst, ... European Respiratory Journal 35 (3), 479-495, 2010 | 769 | 2010 |
2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up J Vansteenkiste, L Crino, C Dooms, JY Douillard, C Faivre-Finn, E Lim, ... Annals of Oncology 25 (8), 1462-1474, 2014 | 552 | 2014 |
Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non–small-cell lung cancer: a … DC Betticher, SF Hsu Schmitz, M Tötsch, E Hansen, C Joss, C Von Briel, ... Journal of Clinical oncology 21 (9), 1752-1759, 2003 | 526 | 2003 |
CD24, a mucin-type glycoprotein, is a ligand for P-selectin on human tumor cells S Aigner, ZM Sthoeger, M Fogel, E Weber, J Zarn, M Ruppert, Y Zeller, ... Blood, The Journal of the American Society of Hematology 89 (9), 3385-3395, 1997 | 456 | 1997 |
Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled … V Galimberti, BF Cole, G Viale, P Veronesi, E Vicini, M Intra, G Mazzarol, ... The Lancet Oncology 19 (10), 1385-1393, 2018 | 449 | 2018 |
2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer WEE Eberhardt, D De Ruysscher, W Weder, C Le Pechoux, P De Leyn, ... Annals of Oncology 26 (8), 1573-1588, 2015 | 433 | 2015 |
Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma W Weder, RA Stahel, J Bernhard, S Bodis, P Vogt, P Ballabeni, ... Annals of oncology 18 (7), 1196-1202, 2007 | 413 | 2007 |
Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes T Le Chevalier, G Scagliotti, R Natale, S Danson, R Rosell, R Stahel, ... Lung cancer 47 (1), 69-80, 2005 | 407 | 2005 |
Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial S Loi, A Giobbie-Hurder, A Gombos, T Bachelot, R Hui, G Curigliano, ... The Lancet Oncology 20 (3), 371-382, 2019 | 404 | 2019 |
Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial M Pless, R Stupp, HB Ris, RA Stahel, W Weder, S Thierstein, MA Gerard, ... The Lancet 386 (9998), 1049-1056, 2015 | 392 | 2015 |
Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer KM Kerr, L Bubendorf, MJ Edelman, A Marchetti, T Mok, S Novello, ... Annals of Oncology 25 (9), 1681-1690, 2014 | 366 | 2014 |
Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation S Hopkins-Donaldson, A Ziegler, S Kurtz, C Bigosch, D Kandioler, ... Cell Death & Differentiation 10 (3), 356-364, 2003 | 359 | 2003 |
Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop R Pirker, FJF Herth, KM Kerr, M Filipits, M Taron, D Gandara, FR Hirsch, ... Journal of Thoracic Oncology 5 (10), 1706-1713, 2010 | 358 | 2010 |
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised … M O’Brien, L Paz-Ares, S Marreaud, U Dafni, K Oselin, L Havel, E Esteban, ... The Lancet Oncology 23 (10), 1274-1286, 2022 | 346 | 2022 |
Circulating DNA: a new diagnostic gold mine? A Ziegler, U Zangemeister-Wittke, RA Stahel Cancer treatment reviews 28 (5), 255-271, 2002 | 345 | 2002 |